Vas Narasimhan, Novartis CEO (Simon Dawson/Bloomberg via Getty Images)
November 18, 2021 09:12 AM EST
Bioregnum

Are the stars lin­ing up for a ma­jor M&A deal at No­var­tis?

Two big things are go­ing on right now at No­var­tis that have the in­vestor crowd on high alert.

First, CEO Vas Narasimhan has sig­naled he …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

A service from the Financial Times